SiloPharma

OCTQB: SILO

Spring 2022

Corporate Presentation

Safe Harbor Statement

This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Silo Pharma At a Glance

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research.

We are committed to developing innovative solutions to address a variety of underserved conditions, including Alzheimer’s, Parkinson's Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.



SiloPharma

The Silo Difference

- While partnering with some of the leading Academic Institutions Silo has licensed therapeutics that will allow the company to pursue the more streamlined 505 (b)(2) route for trials.

- Silo anticipates this strategy will lower cost and allow for a faster approval process to help patients with few if any proven addressable therapeutics.

RED LIGHT HOLLAND

greenbrook gb TMS NeuroHealth Centers

MINDCURE

psyched wellness

HAVN LIFE

field trip

champignon BRANDS

MindMed

Numinus

COMPASS Navigating Mental Health Pathways

MYDECINE INNOVATIONS GROUP

ALGERNON PHARMACEUTICALS

SEELOS THERAPEUTICS

LOBE SCIENCES

Revive Therapeutics

The Silo Advantage

Growing Pipeline of Opportunities

- Psychedelic drugs have shown encouraging promise
- Licensing and funding research with transformative potential

Subtitle Targeting a Breadth of Therapies and Potentially Transformative Assets

- Developing therapeutics for patients suffering from indications such as Alzheimer's, CNS, PTSD, Parkinson's and other rare neurological disorders
- Silo has partnered with leading academic institutions

Gaining Regulatory Support

- Silo has a faster FDA pathway utilizing 505b pathway with various therapeutics in its pipeline

Valuable Intellectual Property

- Silo has been granted patent protection and has filed numerous IP patent applications

Scientific Advisory Board

Josh Woolley, M.D., Ph.D.

Dr. Woolley is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF). He is also a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center (SFVAMC). He received both his M.D. and Ph.D. in Neuroscience from UCSF and also completed his psychiatry residency training at UCSF. Dr. Woolley is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) Laboratory. The mission of the BAND Lab is to understand why people with mental illnesses—including schizophrenia, posttraumatic stress disorder, mood disorders, and substance use disorders—have difficulty making social connections. He also works to develop and test novel treatments for these deficits. His laboratory is actively investigating psilocybin therapy for multiple disorders, including major depressive disorder, bipolar depression, chronic pain, and mood symptoms associated with Parkinson's Disease.

Charles B. Nemeroff, M.D., Ph.D.

Dr. Nemeroff is chair of the Department of Psychiatry and Behavioral Sciences at Dell Medical School, University of Texas at Austin. He also directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He received his medical and doctorate degrees in neurobiology from the University of North Carolina (UNC) School of Medicine. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke University Medical Center and at Emory University School of Medicine before relocating to the University of Miami in 2009. He has served as president of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP) and is on the Scientific Advisory Board of the Brain and Behavior Research Foundation. He is President-elect of the Anxiety and Depression Association of America (ADAA) and is a member of the National Academy of Medicine.

SiloPharma

SPC-14
Targeting Alzheimer's

Market Opportunity: *Alzheimer's Disease*

- 6.5 million of Americans suffer from Alzheimer's and related diseases
- ~1 in 9 Americans 65+ have Alzheimer's
- U.S. market for relevant drugs expected to reach $5 billion by 2027

Technology

- Licensed from Columbia University
- SPC-14 is a novel drug combining two approved therapeutics
- SPC-14 targets NDMARS and 5HT4Rs to treat cognitive and neuropychiatric symptoms in Alzheimers

Regulatory Pathway and Results

- 505b Pathway
- Preclinical testing and POC being lead by inventor Dr. Christine Denny of Columbia University
- SPC-14 has shown reduced hyponeophagia in animal studies
- SPC-14 may reduce behavioral despair.
- Silo has licensed technology with Columbia and has recently entered into a Scientific Research Agreement with Dr. Denny's lab

SiloPharma

SPU-16
CNS Homing Peptide

Market Opportunity:
Multiple Sclerosis (MS)

- There are approximately 400,000 Americans and 2.5 million people worldwide with MS
- The most widespread disabling neurological condition of young adults
- Global market for MS drugs expected to reach $25.3 billion by 2027

Technology

- Licensed from University Maryland Baltimore
- Patent issued
- Central nervous system-homing peptides
- Use for investigation and treatment of MS and other neuroinflammatory pathology

Regulatory Pathway and Results 505b Pathway

- May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord
- May be used for diagnosing and monitoring MS
- Decreases toxicity of existing therapeutics
- Results show much improved delivery of therapeutics and decreased toxicity in animal studies

SiloPharma

SPU-21

Arthritogenic Joint Homing Peptides Utilizing Psilocybin

Market Opportunity:
Rheumatoid Arthritis (RA)

- 1.3M U.S. adults suffer from RA
- The most common autoimmune disease in U.S.
- U.S. market for RA drugs expected to reach $63 billion by 2027

Applications

- Identify markers of arthritic inflammation in joints
- Isolate phage clones that preferentially target inflamed joints of arthritic Lewis rats
- Peptide significantly inhibited arthritic progression in this animal model
- Further studies are underway at UMB

Technology

- Development plan to utilizing liposomal Homing Peptide to deliver targeted psilocybin
- The ability of the peptides to target inflamed epithelium suggest they could be used to target drug delivery. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides can be used to treat autoimmune diseases, including but not limited to RA.

SiloPharma

SPC-15

Targeted prophylactic treatment—Stress-induced affective disorders

Market Opportunity: *Stress-induced Affective Disorders*

- 26% of Americans 18+ suffer from anxiety, PTSD and other disorders
- This number has escalated post-COVID-19
- U.S. market for relevant drugs expected to reach $13 billion by 2027

Technology

- Metabolomic biomarkers predict response to pharmacological treatments
- Utilizes ketamine compositions as a method for treatment and prevention

Applications

- Sponsored Research Agreement with Columbia University Prevention of stress-induced affective disorders
- Increasing stress resilience in military, first responders, and other populations at high risk of PTSD
- Predicting the level of severity or progression such disorders
- Molecular targets for use in drug discovery of innovative treatments

SPC-26
Time-Released Psilocybin, Ketamine

Joint Venture Agreement with Zylö Therapeutics, Inc.

Market Opportunity:

- Multiple Indications

Technology

- Joint Venture with Zylö Therapeutics, Inc.
- Clinical development of psilocybin using ZTI's Z-pod technology
- Clinical development of Zylo's sustained release topical delivery system.

Applications

- Deliver Ketamine or Psilocybin in a time-released manner
- Will time-release diminish the hallucinogenic effects of these psychedelics
- Pre clinical study underway shows Z-pod can hold and distribute Ketamine
- Efficacy study in animals underway

SiloPharma

Clinical Study I:

Repeated Low Doses of Ketamine & Psilocybin on Parkinson's Disease

Investigator-Sponsored Study Agreement—Maastricht University of the Netherlands

Market Opportunity:
Parkinson's Disease

- 1.2M Americans expected to have Parkinson's Disease by 2030
- Parkinson's growing by 50% in Americans between the ages of 30 and 64
- Global market for Parkinson's drugs expected to reach $8.4billion by 2026

Technology

- Repeated low doses of psilocybin and ketamine

Applications

- Better awareness of cognitive and emotional dysfunctions in Parkinson's disease
- Gain understanding of repeated low doses of psilocybin and ketamine and their mechanism of action.

Clinical Study II:
Effect of Psilocybin on Inflammation in the Blood

Sponsored Research Agreement—University of California, San Francisco (UCSF)

Market Opportunity:
Multiple Indications

- Parkinson's Disease, chronic pain, and bipolar disorder.

Technology

- Repeated low doses of psilocybin and ketamine

Applications

- Examine psilocybin's and ketamine's effect on inflammatory activity in humans
- Accelerate its implementation as a potential treatment for Parkinson's Disease, chronic pain, and bipolar disorder.

SiloPharma

Silo's Development Timeline

Drug	Indication	Optimization/ Proof of Concept	Preclinical	Phase I	Phase II	Phase III	Launch	Next Milestone
SPC-14	Alzheimer's							Data expected in Summer 2022
SPU-16	Multiple Sclerosis (MS)							Data on arthritic tissue study expected in June 2022
SPU-21	Rheumatoid Arthritis (RA)							Drug at CRO Liposome: June 2022
SPC-15	Anxiety/PTSD							Dosing data in mice available June 2022
SP-26	Multiple							Data expected in July 2022
Clinical Study I	Parkinson's							Patient enrollment in June 2022
Clinical Study II	Multiple							Data expected Oct-Nov 2022

SiloPharma

Intellectual Property

Patents issued and provisional

US Patent issued 11/16/21 #11174287 Central Nervous System Homing Peptides
US #8,623,377 Joint-Homing peptide

U.S. Provisional Patent Application No. 63/060,573, titled “Central Nervous System Delivery of Psilocybin,” filed August 3, 2020

U.S. Provisional Patent Application No. 63/060,569, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin,” filed August 3, 2020

U.S. Provisional Patent Application No. 63/060,577, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin,” filed August 3, 2020

U.S. Provisional Patent Application No. 63/24,827, titled “Use of Psilocybin in Cancer Treatment,” filed December 13, 2020.

Directors & Director Nominees

Wayne Linsley, Director

Mr. Linsley has served as an independent director of the Company since January 2020. Has a bachelor's in business administration from Siena College in Loudonville, NY. From 2009 to September 2021, he worked for a financial reporting firm that works with publicly traded companies. He has extensive knowledge of financial statements, MD&A, SEC Filings (10K, 10Q, 8K, etc.) Edgar, etc. He often negotiates on behalf of clients in such areas as audit fees, transfer agents, Edgar companies, etc. He currently serves as an independent director for Hoth Therapeutics Inc. (NASDAQ: HOTH) and DatChat Inc. (NASDAQ: DATS).

Kevin Muñoz M.D., Director

Dr. Muñoz currently serves as Director of Operations at Physical Medicine and Rehabilitation, where he has responsibility for the day-to-day management of all office operations with a focus on ensuring and increasing patient satisfaction. Prior to that, he led the configuration efforts during an enterprise-wide implementation of application software that also included streamlining and improving business processes. Kevin began his career with Harlem Health Promotion Center in New York City as a Research Assistant where he was responsible for data collection and interpretation. Dr. Muñoz earned a Bachelor of Science from the University of Michigan where he graduated with distinction and a Doctor of Medicine from Xavier University School of Medicine, Aruba NA.

Jeff Pavell D.O., Director

Dr. Pavell acts as an off-campus site proctor for Rusk Institute residents training for Rehabilitation Medicine and Chief of Rehabilitation Medicine at Englewood Hospital and Medical Center in New Jersey. He graduated from the New York College of Osteopathic Medicine with honors and went on to do his residency and Chief Residency at the New York University Medical Center's Rusk Institute of Rehabilitation and the Bellevue Hospital.

SiloPharma

Executive Leaders

Eric Weisblum, CEO

Mr. Weisblum has over 20 years investing, building and managing businesses. Will lead a scientific advisory board of reputable medical professionals to work and guide the company through the different stages of research, licensing, partnerships and trials. Prior, Mr. Weisblum was President of Sableridge Capital for five years. Eric previously served on the board of directors of Aikido Pharma., a Nasdaq listed biotech company focused on the commercialization of oncology therapeutics.

James Kuo, M.D., MBA, Vice President of R&D

Dr. James (Jim) Kuo currently serves as Managing Director of Athena Bioventures in La Jolla, CA. He is an experienced biotech industry executive and investor who brings financial and management experience to the company. During his career, he has held executive positions in private as well as listed bioscience companies in the U.S., Canada, and Europe. He currently serves as Chairman of the Board of ImmunoPrecise Antibodies and a board director of Tryp Therapeutics. He previously served as CEO of Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery Laboratories. Prior to that, Dr. Kuo was Associate Director in Corporate Licensing and Development at Pfizer and Managing Director of HealthCare Ventures, a $378 million venture fund. He received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business.

Daniel Ryweck CPA, CFO

Mr. Ryweck was a director of Dala Petroleum Corp from July 2016 to September 2017. He served as Chief Compliance Officer of Mill City Ventures III Ltd from 2013 through 2019. From June 2015 through September 2015, he served as interim Chief Financial Officer of Sun BioPharma, Inc. He graduated from the Carlson School of Management at the University of Minnesota in 1990.

SiloPharma

Investment Considerations



Established collaborations with leading academic institutions

Multiple large disease markets being pursued

Strong intellectual property position

Experienced drug development team

Well-capitalized balance sheet

Pursuing up listing to Nasdaq

SiloPharma

thank you.

Eric Weisblum

560 Sylvan Ave, Suite 3160
Englewood Cliffs, NJ 07632

eric@silopharma.com